Pavel Stejskal, MSc is involved in the research that aims to understand the additional value of liquid biopsy as a clinically relevant diagnostic, prognostic and predictive tool. His research is focused on the development of experimental models to explain the biology underlying the release of circulating tumor-related materials into blood. He also focuses on the implementation of complex genomic analyses by liquid biopsy-based biomarkers (circulating tumor cells, circulating tumor DNA, extracellular vesicles, free circulating biomarkers) in the diagnosis, follow-up and therapy of cancer patients.